Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ira Pastan

Showing results (31-40 of 340) with videos related to

Pageof 34
Sort By:
Immunological Reviews|February 12, 2016
Immunogenicity of therapeutic recombinant immunotoxinsRonit Mazor, Masanori Onda, Ira Pastan
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cellsSatoshi Nagata, Tomoko Ise, Ira Pastan
Cellular Immunology|September 15, 2018
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1Ronit Mazor, Emily King, Ira Pastan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
New Life for Immunotoxin Cancer TherapyRaffit Hassan, Christine Alewine, Ira Pastan
Clinical Orthopaedics and Related Research|January 22, 2005
TP-3 immunotoxins improve antitumor activity in mice with osteosarcomaMasanori Onda, Øyvind S Bruland, Ira Pastan
The American Journal of Pathology|June 6, 2018
Strategies to Reduce the Immunogenicity of Recombinant ImmunotoxinsRonit Mazor, Emily M King, Ira Pastan
Methods in Molecular Biology (Clifton, N.J.)|February 19, 2004
Recombinant immunotoxins in the treatment of cancerIra Pastan, Richard Beers, Tapan K Bera
Plos One|October 17, 2013
Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1PAbid R Mattoo, Ira Pastan, David Fitzgerald
Oncotarget|April 21, 2017
Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignanciesFabian Müller, Stephanie Stookey, Tyler Cunningham, et al.
Cancer Research|January 26, 2013
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxinXiu Fen Liu, David J FitzGerald, Ira Pastan
Pageof 34

Showing results (31-40 of 340) with videos related to

Sort By:
Pageof 34
Immunological Reviews|February 12, 2016
Immunogenicity of therapeutic recombinant immunotoxinsRonit Mazor, Masanori Onda, Ira Pastan
Journal of Immunology (Baltimore, Md. : 1950)|June 5, 2009
Fc receptor-like 3 protein expressed on IL-2 nonresponsive subset of human regulatory T cellsSatoshi Nagata, Tomoko Ise, Ira Pastan
Cellular Immunology|September 15, 2018
Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1Ronit Mazor, Emily King, Ira Pastan
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
New Life for Immunotoxin Cancer TherapyRaffit Hassan, Christine Alewine, Ira Pastan
Clinical Orthopaedics and Related Research|January 22, 2005
TP-3 immunotoxins improve antitumor activity in mice with osteosarcomaMasanori Onda, Øyvind S Bruland, Ira Pastan
The American Journal of Pathology|June 6, 2018
Strategies to Reduce the Immunogenicity of Recombinant ImmunotoxinsRonit Mazor, Emily M King, Ira Pastan
Methods in Molecular Biology (Clifton, N.J.)|February 19, 2004
Recombinant immunotoxins in the treatment of cancerIra Pastan, Richard Beers, Tapan K Bera
Plos One|October 17, 2013
Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1PAbid R Mattoo, Ira Pastan, David Fitzgerald
Oncotarget|April 21, 2017
Paclitaxel synergizes with exposure time adjusted CD22-targeting immunotoxins against B-cell malignanciesFabian Müller, Stephanie Stookey, Tyler Cunningham, et al.
Cancer Research|January 26, 2013
The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxinXiu Fen Liu, David J FitzGerald, Ira Pastan
Pageof 34